[go: up one dir, main page]

US10385095B2 - Methods for extracting keratin proteins - Google Patents

Methods for extracting keratin proteins Download PDF

Info

Publication number
US10385095B2
US10385095B2 US14/238,648 US201214238648A US10385095B2 US 10385095 B2 US10385095 B2 US 10385095B2 US 201214238648 A US201214238648 A US 201214238648A US 10385095 B2 US10385095 B2 US 10385095B2
Authority
US
United States
Prior art keywords
keratin
solution
protein
keratin protein
kerateine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US14/238,648
Other languages
English (en)
Other versions
US20150080552A1 (en
Inventor
Luke Burnett
Sarah Ann Boyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keranetics LLC
Original Assignee
Keratin Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keratin Biosciences Inc filed Critical Keratin Biosciences Inc
Priority to US14/238,648 priority Critical patent/US10385095B2/en
Publication of US20150080552A1 publication Critical patent/US20150080552A1/en
Assigned to KeraNetics, LLC reassignment KeraNetics, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BURNETT, LUKE
Assigned to KeraNetics, LLC reassignment KeraNetics, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BOYD, Sarah Ann
Assigned to KERATIN BIOSCIENCES, INC. reassignment KERATIN BIOSCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KERANETICS LLC
Application granted granted Critical
Publication of US10385095B2 publication Critical patent/US10385095B2/en
Assigned to KERANETICS, INC reassignment KERANETICS, INC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: KERATIN BIOSCIENCES INC.
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin

Definitions

  • This invention relates to methods to extract and purify keratin protein-based biomaterials.
  • Keratins are a family of proteins found in the hair, skin, and other tissues of vertebrates. Hair is a unique source of human keratins because it is one of the few human tissues that are readily available and inexpensive. Although other sources of keratins are acceptable feedstocks for the present invention (e.g. wool, fur, horns, hooves, beaks, feathers, scales, and the like), human hair is preferred because of its biocompatibility in human medical applications.
  • Keratins can be extracted from human hair fibers by oxidation or reduction using methods that have been widely published in the art. If one employs a reductive treatment, the resulting keratins are referred to as kerateines. If an oxidative treatment is used, the resulting keratins are referred to as keratoses. These methods typically employ a two-step process whereby the crosslinked structure of keratins is broken down by either oxidation or reduction. In these reactions, the disulfide bonds in cystine amino acid residues are cleaved, rendering the keratins soluble without appreciable disruption of amide bonds.
  • a second-step using a denaturing solution is typically employed to effect efficient extraction of the cortical proteins (alternatively, in the case of oxidation reactions, these steps can be combined).
  • This step has also been widely published in the art as solutions such as urea, transition metal hydroxides, surfactant solutions, and combinations thereof have been employed. Common methods include the use of aqueous solutions of tris(hydroxymethyl) aminomethane in concentrations between 0.1 and 1.0M, and urea solutions between 0.1 and 10M.
  • the invention provides methods to produce keratin protein-based biomaterials, the parameters required to achieve improved extraction, the parameters required to improve isolation, the parameters of lyophilization and the grinding process to achieve consistent particulate sizes of protein materials.
  • the invention also provides methods to extract keratin proteins comprising: a) treating a keratin protein source with an oxidizing or reducing agent to solubilize keratin proteins; b) separating the soluble proteins from the keratin protein source by high speed centrifugation to produce a clarified soluble keratin protein solution; and c) lyophilizing the clarified soluble keratin protein solution into a keratin protein cake, wherein degradation of said keratin protein is minimized.
  • the invention also provides methods to extract keratin proteins comprising: a) treating a keratin protein source with an oxidizing or reducing agent to solubilize keratin proteins; b) separating the soluble proteins from the keratin protein source by high speed centrifugation to produce a clarified soluble keratin protein solution; and c) dialyzing the clarified soluble keratin protein solution wherein degradation of said keratin protein is minimized.
  • FIG. 1 depicts a cartoon showing a potential mixing container that provides mechanical agitation
  • FIG. 2 is a scanning electron micrograph of hair shafts after 12 hours of mechanical mixing in the presence of an oxidant.
  • FIG. 3 depicts hair after base extraction.
  • FIG. 3A is a picture of hair after base extraction.
  • FIG. 3B is a scanning electron micrograph of a hair shaft after base extraction. The shaft is split in half and the majority of its cortical proteins (alpha and gamma keratins) have been removed during extraction, leaving the outer beta keratin hair covering.
  • FIG. 4 is a scanning electron micrograph of hair shafts after final water extraction. The majority of cortical proteins are extracted and only the residual beta keratin hard coverings of the hair shafts appear to remain.
  • Keratin protein source as used herein includes proteinaceous sources of keratin proteins including but not limited human or animal wool, fur, horns, hooves, beaks, feathers, scales, and the like.
  • Keratin protein(s) as used herein collectively refers to keratin in keratin protein sources, including but not limited to naturally occurring keratin, reduced keratin, and/or oxidized keratin, or S-sulfonated keratin. This term also refers to the extracted keratin derivatives that are produced by oxidative and/or reductive treatment of keratin, including but not limited to keratose, alpha-keratose, gamma-keratose, kerateine, alpha-kerateine, or gamma-kerateine.
  • “Clarified keratin protein solution” as used herein refers to a solution comprising extracted keratin proteins that has undergone at least one high speed centrifugation step to clarify the solution of other contaminants.
  • Keratin protein cake includes but is not limited to a freeze-dried and/or vacuum dried keratin protein composition that exhibits long-term stability, short reconstitution time, uniform appearance, and low moisture content. Further, in some embodiments, “keratin protein cake”, “lyophilized protein cake”, or “protein cake” refers to compositions substantially free of bulking agents or stabilizers.
  • Keratins are a family of proteins found in the hair, skin, and other tissues of vertebrates. Hair is a common source of human keratins because it is one of the few human tissues that is readily available and inexpensive. Other sources of keratins are acceptable feedstocks for the present invention, (e.g., wool, fur, horns, hooves, beaks, feathers, scales, and the like). Human hair is often used with human subjects because of its biocompatibility. Accordingly, in some embodiments, human hair is the keratin protein source The human hair can be end-cut, as one would typically find in a barber shop or salon.
  • Soluble keratins can be extracted from human hair fibers by oxidation or reduction using methods known in the art. These methods typically employ a two-step process whereby the crosslinked structure of keratins is broken down by either oxidation or reduction. In these reactions, the disulfide bonds in cystine amino acid residues are cleaved, rendering the keratins soluble. The cuticle is essentially unaffected by this treatment, so the majority of the keratins remain trapped within the cuticle's protective structure. In order to extract these keratins, a second step using a denaturing solution is employed. Alternatively, in the case of reduction reactions, these steps can be combined.
  • Denaturing solutions known in the art include urea, transition metal hydroxides, surfactant solutions, and combinations thereof. Common methods use aqueous solutions of tris base (2-Amino-2-(hydroxymethyl)-1,3-propanediol) in concentrations between 0.1 and 1.0 M, and urea solutions between 0.1 and 10M, for oxidation and reduction reactions, respectively.
  • the resulting keratins are referred to as “keratoses.” If a reductive treatment is used, the resulting keratins are referred to as “kerateines.”
  • Crude (unfractionated) extracts of keratins can be further refined into matrix (KAP and gamma), alpha, and/or charged (acidic or basic) fractions by a variety of methods such as isoelectric precipitation, dialysis, or high performance liquid chromatography (HPLC), as desired.
  • KAP and gamma matrix
  • alpha alpha
  • amino acid fractions a fraction of keratins
  • HPLC high performance liquid chromatography
  • KAP co-precipitate with the alpha fraction, thereby producing an alpha/KAP mixture.
  • High molecular weight keratins or “alpha keratins,” (alpha helical), are thought to originate from the microfibrillar regions of the hair follicle, and typically range in molecular weight from about 40-50 kiloDaltons for monomers and 80-100 kiloDaltons for dimers.
  • Low molecular weight keratins, or “gamma keratins,” or keratin-associated proteins (globular) are thought to originate from the matrix regions of the hair follicle, and typically range in molecular weight from about 3-30 kiloDaltons for KAP and 10-15 kiloDaltons for gamma keratins
  • the keratin preparations (particularly alpha and/or gamma kerateine and alpha and/or gamma-keratose) have an average molecular weight of from about 10 to about 70 or about 85 or about 100 kiloDaltons.
  • alpha and gamma keratins possess unique properties, the properties of subfamilies of both alpha and gamma keratins can only be revealed through more sophisticated means of purification and separation such as provided herein. Additional properties that are beneficial emerge and can be optimized upon further separation and purification of crude keratin extracts.
  • One method for the production of keratoses is by oxidation of keratin with hydrogen peroxide, peracetic acid, or performic acid.
  • the oxidant is peracetic acid.
  • a solution of peracetic acid is used at a concentration range of about 1% to about 10%.
  • a specific concentration used can be a 2% solution of peracetic acid.
  • the oxidant concentrations range from a ratio of about 5:1 to about 50:1 weight to weight to the keratin protein source to be extracted.
  • a specific embodiment uses a weight to weight ratio of 25:1 of a 2% peracetic acid solution.
  • the weight to weight ratio is about 30:1 Those skilled in the art will recognize that slight modifications to the concentration can be made to affect varying degree of oxidation, with concomitant alterations in reaction time, temperature, and liquid to solid ratio. It has also been discussed that performic acid offers the advantage of minimal peptide bond cleavage compared to peracetic acid. However, peracetic acid offers the advantages of cost and availability.
  • the oxidation temperature is between 0 and 100° Celsius. In a specific embodiment, the oxidation temperature is 37° C. In some embodiments, the oxidation time is between 0.5 and 24 hours. In a specific embodiment, the oxidation time is 12 hours. In some embodiments, mechanical mixing is used to maximize oxidation efficiency.
  • the keratin protein source can be rinsed free of residual oxidant using copious amounts of purified water.
  • the oxidized keratin protein source is washed with water until residual oxidant is removed.
  • the washing step is performed until the washed keratin protein source does not test positive for oxidant.
  • the washed keratin protein source has about 5 ppm or less residual oxidant.
  • the keratoses may be extracted from the oxidized keratin protein source using an aqueous solution of a denaturing agent.
  • Protein denaturants are well known in the art, including but not limited to, urea, transition metal hydroxides (e.g. sodium and potassium hydroxide), ammonium hydroxide, and tris(hydroxymethyl)aminomethane (Tris, also known as Trizma® base).
  • Tris is used at a ratio of about 5:1 to about 50:1 weight of protein source to a Tris solution of a concentration of about 0.01 to 1M. In other specific embodiments, the ratio is 25:1 or 40:1. In another specific embodiment, Tris is used at a concentration of 100 mM.
  • the extraction temperature is between 0° and 100° Celsius. In a specific embodiment, the extraction temperature is 37° C. In some embodiments, the extraction time is between 0.5 and 24 hours. In a specific embodiment, the extraction time is about 2 hours. Additional yield can be achieved with subsequent extractions with dilute solutions of Tris or purified water. Often, the extraction is performed with mechanical agitation in a mixing tank to ensure a more efficient yield.
  • kerateines can be produced by reduction of a keratin protein source with thioglycolic acid or beta-mercaptoethanol.
  • thioglycolic acid TGA
  • TGA is often used.
  • TGA is added to the keratin protein source at a ratio of about 5:1 to about 50:1.
  • TGA is added at a ratio of 25:1.
  • the TGA is added at a solution ranging in concentrations from about 0.1 to about 10M.
  • the TGA is added in solution at a concentration of 0.5M.
  • mechanical agitation is used to maximize extraction efficiency.
  • the solution containing reductant and extracted kerateine proteins (soluble keratin protein solution) is the collected and stored by straining the keratin protein source through a 400 micron mesh and storing the solution at 4° C.
  • a base is then added to the drained keratin protein source in a ratio of about 10:1 to about 50:1.
  • the base is added to the drained keratin protein source at a ratio of 25:1.
  • the base is Tris generally used at a concentration of about 100 mM.
  • the keratin protein source in the solution with base is mixed with agitation of about 2 hours at 37° C.
  • the solution containing the base and extracted keratin proteins (soluble keratin protein solution) is then filtered and added to the first extracted solution and stored.
  • the reduction is performed at a temperature between 0 and 100° Celsius. In a specific embodiment, the temperature is 37° C. In some embodiments, the reduction time is between 0.5 and 24 hours. In a specific embodiment, the reduction is performed for 15 hours.
  • reduction is carried out at basic pH. That being the case, keratins are highly soluble in the reduction media and are expected to be extracted. The reduction solution may therefore be combined with the subsequent extraction solutions and processed accordingly. The reduction is carried out with mechanical agitation in a mix tank to increase the efficiency of the reduction of the keratin proteins.
  • Residual reductant and denaturing agents can be removed from solution by dialysis. Typical dialysis conditions are 1 to 2% solution of kerateines dialyzed against purified water. Those skilled in the art will recognize that other methods exist for the removal of low molecular weight contaminants in addition to dialysis (e.g. microfiltration, chromatography, and the like). Once dissolved, the kerateines are stable in solution without the denaturing agent for finite periods. Therefore, the denaturing agent can be removed without the resultant precipitation of kerateines. Regardless of the fractionation/purification process, the resulting kerateines can be concentrated and lyophilized, similar to keratoses.
  • a soluble keratin protein solution is produced by the extraction of keratose and/or kerateine by either oxidative means for keratose, or by reductive means for kerateine.
  • the soluble keratin protein solution may comprise 80%, 85%, 90%, 95%, 99% or more keratose.
  • the keratose may be alpha-keratose or gamma-keratose, or some combination thereof.
  • the keratose in the soluble keratin protein solution comprises 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more alpha-keratose.
  • the keratose in the soluble keratin protein solution comprises 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more gamma-keratose.
  • the soluble keratin protein solution may comprise 80%, 85%, 90%, 95%, 99% or more kerateine.
  • the kerateine may be alpha-kerateine or gamma kerateine, or some combination thereof.
  • the kerateine in the soluble keratin protein solution comprises 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more alpha-kerateine.
  • the kerateine in the soluble keratin protein solution comprises 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more gamma-kerateine.
  • a high speed centrifugation step is used.
  • Current methods known in the art generally use a low speed centrifugation (around 4,000 rpm) to clear particulate matter. However, this speed does not create enough force to remove many of the protein contaminants present in the extracted protein solution.
  • high speed centrifugation is employed. Speeds in excess of about 5,000 rpm to about 30,000 rpm can be used.
  • the extracted protein solution is spun at about 20,000 rpm to produce a clarified protein solution.
  • the high speed centrifugation step is performed at about 4° C.
  • a clarified protein solution is produced by the high speed centrifugation of the soluble keratin protein solution.
  • the clarified protein solution may comprise 80%, 85%, 90%, 95%, 99% or more keratose.
  • the keratose may be alpha-keratose or gamma-keratose, or some combination thereof.
  • the keratose in the clarified protein solution comprises 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more alpha-keratose.
  • the keratose in the clarified protein solution comprises 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more gamma-keratose.
  • the clarified protein solution may comprise 80%, 85%, 90%, 95%, 99% or more kerateine.
  • the kerateine may be alpha-kerateine or gamma kerateine, or some combination thereof.
  • the kerateine in the clarified protein solution comprises 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more alpha-kerateine.
  • the kerateine in the clarified protein solution comprises 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more gamma-kerateine.
  • dialysis is used to separate or even to concentrate certain protein species present in the sample. Accordingly here, in many embodiments, the clarified protein solution is subjected to a dialysis step to fractionate certain protein species.
  • a 100 kDa molecular weight cutoff membrane is employed in the purification of alpha-keratose or alpha-kerateine. In other embodiments, a 5 kDa molecular weight cutoff membrane is employed to purify gamma-keratose or gamma kerateine.
  • a common matrix for the dialysis membranes is regenerated cellulose, however, many other membrane preparations suitable for protein purification may be used.
  • the dialysis is performed under conditions that maintain a transmembrane pressure from about 30 psi to about 40 psi (alpha) and about 50 psi to about 70 psi (gamma). Further, it is important to minimize the heat buildup developed by the shear stress of pressurized dialysis. Thus, in some embodiments, the dialysis is carried out at a temperature from about 4° C. to about 20° C. In a specific embodiment, the dialysis is carried out at about 15° C. to about 20° C.
  • the conductivity is adjusted. In some embodiments, the conductivity is adjusted down to about or below 0.6 mS. In some instances, the conductivity is adjusted with water.
  • the clarified protein solution may comprise 80%, 85%, 90%, 95%, 99% or more keratose.
  • the keratose may be alpha-keratose or gamma-keratose, or some combination thereof.
  • the keratose in the clarified protein solution post dialysis comprises 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more alpha-keratose.
  • the keratose in the clarified protein solution post dialysis comprises 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more gamma-keratose.
  • the clarified protein solution post dialysis is substantially free of alpha-keratose.
  • the clarified protein solution post dialysis is substantially free of gamma-keratose.
  • the clarified protein solution may comprise 80%, 85%, 90%, 95%, 99% or more kerateine.
  • the kerateine may be alpha-kerateine or gamma-kerateine, or some combination thereof.
  • the kerateine in the clarified protein solution post dialysis comprises 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more alpha-kerateine.
  • the kerateine in the clarified protein solution post dialysis comprises 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more gamma-kerateine.
  • the clarified protein solution post dialysis is substantially free of alpha-kerateine.
  • the clarified protein solution post dialysis is substantially free of gamma-kerateine.
  • proteins for any length of time can pose stability problems. While working with proteins in the lab, they should be kept on ice. Since proteins are generally more stable at colder temperatures, maintenance at low temperatures even for short duration is recommended. Typically, proteins can be freeze-dried (lyophilized) to achieve storage conditions while maintaining protein stability.
  • lyophilization is used to produce a protein cake of purified protein post-dialysis.
  • the lyophilization is used to stabilize the extracted keratin proteins.
  • Methods known in the art such as shell freezing followed by vacuum or bulk freezing and applying high heat tend to degrade proteins.
  • a keratin protein cake, comprising keratose and/or kerateine is produced by a lyophilization of a clarified keratin protein solution, optionally after dialysis.
  • the clarified protein solution post-dialysis is bulk frozen at about ⁇ 40° C., then a vacuum is applied until the containment containing the solution reaches about 250 torr.
  • heat is then applied in a step-wise fashion, bringing the material to about 0° C., then to about 25° C., then to about 37° C., while maintaining 250 torr pressure.
  • the lyophilization process occurs over a 24 hour period.
  • the keratin protein cake may comprise 80%, 85%, 90%, 95%, 99% or more keratose.
  • the keratose may be alpha-keratose or gamma-keratose, or some combination thereof.
  • the keratose in the keratin protein cake comprises 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more alpha-keratose.
  • the keratose in the keratin protein cake comprises 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more gamma-keratose.
  • the keratin protein cake is substantially free of alpha-keratose.
  • the keratin protein cake is substantially free of gamma-keratose.
  • the keratin protein cake may comprise 80%, 85%, 90%, 95%, 99% or more kerateine.
  • the kerateine may be alpha-kerateine or gamma-kerateine, or some combination thereof.
  • the kerateine in the keratin protein cake comprises 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more alpha-kerateine.
  • the kerateine in the keratin protein cake comprises 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more gamma-kerateine.
  • the keratin protein cake is substantially free of alpha-kerateine.
  • the keratin protein cake is substantially free of gamma-kerateine.
  • Precise grinding of the lyophilized material aids in the homogeneity of reconstitution and protein stability.
  • Previous methods involve crude grinding methods, including grinding or chopping of the material in a household blender.
  • some embodiments employ a commercial grinding apparatus to machine the material to a homogenous particle size.
  • a pharmaceutical mill is employed.
  • the particle size is 1 millimeter or less in diameter.
  • the ground material has been deionized.
  • Untreated Chinese hair was used in the extraction method.
  • the hair was end-cut to lengths of 1 ⁇ 4, 1 ⁇ 2, 3 ⁇ 4 and 1 inch segments and cleaned by washing in a warm water solution.
  • Step 1 The hair was added to a mixing tank.
  • the tank was a 316L stainless steel vessel that contained a propeller for mechanical agitation (see FIG. 1 ).
  • the oxidant was added to the vessel.
  • the oxidant used was a 2% solution of paracetic acid (PAA) at a 25:1 weight-to-weight ratio.
  • PAA paracetic acid
  • the mixture was mechanically mixed for a period of 12 hours at 37° C. The mechanical mixing resulted in complete oxidation of the hair shafts (see FIG. 2 ).
  • Step 2 The residual solution containing the oxidant was drained, neutralized and discarded.
  • Step 3 The oxidized hair was collected and rinsed with water until PAA test strips revealed no residual oxidant in the solution.
  • Step 4 A base was then added to the drained hair in a ratio of 25:1.
  • a 100 mM Tris base was used.
  • the solution was mixed with mechanical agitation in the mixing tank for 2 hours at 37° C.
  • FIG. 3 shows hair that has completed this extraction step.
  • Step 5 The solution containing base and extracted keratin proteins was then collected and stored in a separate container at 4° C. The remaining hair was retained by sieving through a steel mesh with a pore size of the mesh of 400 microns. The mechanical agitation employed in this step helped to remove any residual extracted solution from the remaining hair mass.
  • Step 6 Purified water was then added to the hair at a ratio of 25:1 and mixed for 2 hours at 37° C.
  • Step 7 The solution containing water and extracted keratin proteins was then collected and added to the solution from Step 5 in a separate container stored at 4° C.
  • the hair was sieved through a steel mesh with a pore size of 400 microns
  • the mechanical agitation employed ensures removal of any residual extracted solution from the remaining hair mass.
  • FIG. 4 shows the hair shafts after the final water extraction.
  • Step 8 The combined mixture from Step 5 and Step 7 was then centrifuged at 20,000 rpm to remove any solids or beta-keratins. Centrifugation at speeds at or below 4,000 rpm does not fully remove residual solids, contributing to poor dialysis and final product.
  • Step 9 The centrifuged solution was filtered with a 20 micrometer pore size capsule filter.
  • Step 10 The solution from Step 9 was dialyzed against a 100 kDa molecular weight cut off dialysis membrane, made from regenerated cellulose, using standard tangential flow filtration. It can be beneficial to cool the solution to minimize heat from shear forces on pumps. It can also be beneficial to maintain trans-membrane pressures between 30-40 psi during the dialysis process. Lower pressures result in solutions that contain greater protein fragments and peptides, higher pressures result in protein complex degradation. The solution was dialyzed until the conductivity reached 0.6 mS using additions of purified water to replace permeate. The first complete solution wash was collected and stored in a storage tank at 4° C.
  • Step 11 The solution from Step 10 was then lyophilized into a keratin protein cake of alpha keratose.
  • the lyophilization step helps maintain intact keratin proteins.
  • the solution was bulk frozen to ⁇ 40° C. quickly then had a vacuum applied until the containment vessel containing the protein reached 250 torr. Heat was then applied in a step-wise fashion to bring the material first to 0° C., then to 25° C., then to 37° C. while maintaining 250 torr. The temperature was maintained at 37° C. in order to prevent degradation during the drying process.
  • Step 12 The first wash solution from Step 10 (containing gamma-keratose) was dialyzed against a 5 kDa molecular weight cut off dialysis membrane made from regenerated cellulose, using standard tangential flow filtration methods. The solution was cooled to minimize the heat build-up from shear forces on the pumps. Also, the trans-membrane pressures were maintained between 50-70 psi during the dialysis process. Lower pressures result in solutions that contain greater protein fragments and peptides, higher pressures result in protein complex degradation. The solution was dialyzed until the conductivity reached 0.6 mS using additions of purified water to replace permeate.
  • Step 13 The solution from Step 12 was lyophilized into a keratin protein cake of gamma-keratose.
  • the solution containing the gamma-keratose was bulk frozen at ⁇ 40° C. quickly then a vacuum was applied until the containment vessel containing the protein reached 250 torr. Heat was then applied in a step-wise fashion to bring the material first to 0° C., then to 25° C., then to 37° C. while maintaining 250 torr.
  • the mixture was maintained at 4° C. Elevated temperatures in the method were avoided in order to prevent degradation during the drying process.
  • Step 14 The keratin protein cakes from Step 11 and 13 were independently ground using a pharmaceutical mill with a mesh size of 1 millimeter. The ground protein was deionized to better allow further processing. The ground protein was then placed in sterile bags and is now ready for use in a variety of medical and research applications.
  • Untreated Chinese hair was end-cut to lengths of 1 ⁇ 4, 1 ⁇ 2, 3 ⁇ 4 and 1 inch segments and washed in a warm water solution.
  • Step 1 The hair was added to a 316L stainless steel vessel that contained a propeller for mechanical agitation (see FIG. 1 ).
  • the reductant was added to the vessel.
  • the reductant was a 0.5M solution of a thioglycolic acid (TGA) at a ratio of 25:1.
  • TGA thioglycolic acid
  • the mixture was mechanically mixed for a period of 15 hours at 37° C. The mechanical mixing can be beneficial to improve the extent to which reduction occurs in the hair shafts.
  • Step 2 The solution containing reductant and extracted keratin proteins was collected and stored in a separate container at 4° C. The remaining hair was retained by sieving through a steel mesh with a pore size of 400 microns. The mechanical agitation applied during the straining process helps to collect as much solution as possible from the hair mass.
  • Step 3 A base was then added to the drained hair in a ratio of 25:1.
  • the base used here was a 100 mM Tris base solution.
  • the solution was mixed with mechanical agitation in a mixing tank for 2 hours at 37° C.
  • Step 4 The solution containing base and extracted keratin proteins was collected and added to the solution from Step 2 and stored at 4° C. The remaining hair was retained by sieving through a steel mesh with a pore size of 400 microns. The mechanical agitation applied during the straining process helps to collect as much solution from the hair mass.
  • Step 5 Purified water was added to the hair at a ratio of 25:1 and mixed for 2 hours at 37° C.
  • Step 6 The solution containing water and extracted keratin proteins was collected and added to the solution from Step 4 and stored at 4° C. In order to maximize extraction yield, the hair was sieved through a steel mesh with a pore size of 400 microns. Mechanical agitation was applied during the straining process to strain as much solution as possible from the hair mass.
  • Step 7 A second reduction step was needed to fully extract the keratin proteins from the hair shaft.
  • the reductant used was a 0.5M solution of a thioglycolic acid (TGA) at a ratio of 25:1.
  • TGA thioglycolic acid
  • the mixture was mechanically mixed for a period of 15 hours at 37° C. Mechanical mixing was used to ensure complete reduction of the hair shafts.
  • Step 8 The solution containing reductant and extracted keratin proteins was collected and stored in a separate vessel containing the solution from Step 6 and stored at 4° C. The remaining hair was retained by sieving through a steel mesh with a pore size of 400 microns. Mechanical agitation applied during the straining process helps to strain as much solution from the hair mass.
  • Step 9 A base was added to the drained hair in a ratio of 25:1.
  • the base used was a 100 mM Tris base solution.
  • the solution was mixed with mechanical agitation in a mixing tank for 2 hours at 37° C.
  • Step 10 The solution containing base and extracted keratin proteins was then collected and added to the solution from Step 8 and stored at 4° C. The remaining hair was retained by sieving through a steel mesh with a pore size of 400 microns. Mechanical agitation applied during the straining process helps to strain as much solution as possible from the hair mass.
  • Step 11 Purified water was then added to the hair at a ratio of 25:1 and mixed for 2 hours at 37° C.
  • Step 12 The solution containing water and extracted keratin proteins was collected and added to the solution from Step 10 stored at 4° C. In order to get the maximum extraction yield, the hair was sieved through a steel mesh of a pore size of 400 microns. Again, mechanical agitation applied during the straining process helps to strain as much solution as possible from the hair mass.
  • Step 13 The combined mixture from Steps 12, 10, 8, 6, 4, and 2 was centrifuged at 20,000 rpm to remove any solids or beta keratins. Centrifugation at speeds at or below 4,000 rpm does not fully remove residual solids, contributing to poor dialysis and final product.
  • Step 14 The centrifuged solution was filtered with a 20 micrometer pore size capsule filter.
  • Step 15 The solution from Step 14 was dialyzed against a 100 kDa molecular weight cut off regenerated cellulose dialysis membrane using standard tangential flow filtration methods. The solution was cooled to dissipate the heat from shear forces on pumps. Also, trans-membrane pressures were maintained between 30-40 psi during the dialysis process. The solution was dialyzed until the conductivity lowered from 24 mS to 0.6 mS using additions of purified water to replace permeate. This required about 5 complete volume changes (or washes) and left some residual TGA in the solution. The TGA can be completely removed by dialyzing until the conductivity reaches 0 mS or 12-20 volume changes. The first complete solution wash was collected and stored in a storage tank at 4° C.
  • Step 16 The solution from Step 15 was lyophilized into a keratin protein cake of alpha keratin.
  • a lyophilization step was used to maintain intact keratin proteins.
  • methods that are known in the art such as shell freezing followed by vacuum or bulk freezing and applying high heat tend to degrade the proteins.
  • the lyophilization step was to bulk freeze the solution to ⁇ 40° C. quickly then apply a vacuum until the containment vessel containing the protein reached 250 torr. Heat was applied in a step-wise fashion to bring the material first to 0° C., then to 25° C., then to 37° C. while maintaining 250 torr. The temperature was not allowed to exceed 37° C. in order to prevent degradation during the drying process.
  • Step 17 The first wash solution from Step 15 (gamma kerateine) was dialyzed against a 5 kDa molecular weight cut off regenerated cellulose dialysis membrane using standard tangential flow filtration methods. Heat from shear forces on pumps was minimized by cooling the solution. Also, trans-membrane pressures between 50-70 psi were maintained during the dialysis process. Lower pressures result in solutions that contain greater protein fragments and peptides, higher pressures result in protein complex degradation. The solution was dialyzed until the conductivity reached 0.6 mS using additions of purified water to replace permeate.
  • Step 18 The solution from Step 17 was lyophilized into a keratin protein cake of gamma-kerateine.
  • lyophilization was accomplished by bulk freezing the solution to ⁇ 40° C. quickly then applying a vacuum until the containment vessel containing the protein reached 250 torr. Heat was then applied in a step-wise fashion to bring the material first to 0° C., then to 25° C., then to 37° C. while maintaining 250 torr. The temperature was not allowed to exceed 37° C. in order to prevent degradation during the drying process.
  • Step 19 The keratin protein cakes from Step 18 and 16 were independently ground using a pharmaceutical mill with a mesh size of 1 millimeter. The ground protein was deionized to better allow further processing. The ground protein was then placed in sterile bags and is now ready for use in a variety of medical and research applications.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
US14/238,648 2011-08-17 2012-08-16 Methods for extracting keratin proteins Active 2032-12-13 US10385095B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/238,648 US10385095B2 (en) 2011-08-17 2012-08-16 Methods for extracting keratin proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524541P 2011-08-17 2011-08-17
US14/238,648 US10385095B2 (en) 2011-08-17 2012-08-16 Methods for extracting keratin proteins
PCT/US2012/051192 WO2013025928A2 (fr) 2011-08-17 2012-08-16 Procédés d'extraction de protéines de la kératine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/051192 A-371-Of-International WO2013025928A2 (fr) 2011-08-17 2012-08-16 Procédés d'extraction de protéines de la kératine

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/507,181 Continuation US11034722B2 (en) 2011-08-17 2019-07-10 Methods for extracting keratin proteins
US16/507,181 Division US11034722B2 (en) 2011-08-17 2019-07-10 Methods for extracting keratin proteins

Publications (2)

Publication Number Publication Date
US20150080552A1 US20150080552A1 (en) 2015-03-19
US10385095B2 true US10385095B2 (en) 2019-08-20

Family

ID=47715700

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/238,648 Active 2032-12-13 US10385095B2 (en) 2011-08-17 2012-08-16 Methods for extracting keratin proteins
US16/507,181 Active US11034722B2 (en) 2011-08-17 2019-07-10 Methods for extracting keratin proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/507,181 Active US11034722B2 (en) 2011-08-17 2019-07-10 Methods for extracting keratin proteins

Country Status (5)

Country Link
US (2) US10385095B2 (fr)
EP (2) EP3412683B1 (fr)
AU (1) AU2012296477B2 (fr)
CA (1) CA2845266C (fr)
WO (1) WO2013025928A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2845266C (fr) 2011-08-17 2020-07-21 Keranetics Llc Procedes d'extraction de proteines de la keratine
WO2013025941A1 (fr) 2011-08-17 2013-02-21 Keranetics Llc Compositions gélifiantes à faible concentration en protéines
US10792239B2 (en) 2012-11-06 2020-10-06 Kernnetics, Inc. White keratin compositions
US11505587B2 (en) * 2013-01-18 2022-11-22 Nanyang Technological University Method of preparing a keratin-based biomaterial and keratin-based biomaterial formed thereof
TN2018000135A1 (fr) * 2018-04-24 2019-10-04 Ghidhaoui Abir Extraction et exploitation de Kératine béta, la Kératine béta et ses dérivées.
TWI679210B (zh) * 2018-10-05 2019-12-11 光隆實業股份有限公司 從羽毛獲得角蛋白的方法
CN109575119A (zh) * 2018-12-25 2019-04-05 广州美炫化妆品有限公司 兔毛角蛋白的新型提取方法及其在化妆品中的应用
US20230192762A1 (en) * 2020-04-17 2023-06-22 Nanyang Technological University Keratin Filament Networks
CN113512104A (zh) * 2021-04-27 2021-10-19 安徽科技学院 一种猪蹄甲角蛋白制备方法
CN118598974B (zh) * 2024-07-12 2025-03-18 华中农业大学 通过高碘酸盐氧化提取蛋白质多级结构的方法

Citations (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB351600A (en) 1930-04-04 1931-07-02 Ig Farbenindustrie Ag Improvements in the culture of micro-organisms intended for unhairing purposes
US2993794A (en) 1958-06-25 1961-07-25 Gen Foods Corp Process for preparing keratin protein
US3464825A (en) 1967-02-28 1969-09-02 Gen Mills Inc Keratin protein product and process of preparing same
US4570629A (en) 1982-03-17 1986-02-18 University Of Illinois Foundation Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same
US5006467A (en) 1987-07-03 1991-04-09 Mitsubishi Kasei Corporation Cell culture microcarriers
US5047249A (en) 1988-07-22 1991-09-10 John Morris Co., Inc. Compositions and methods for treating skin conditions and promoting wound healing
US5100783A (en) 1985-05-10 1992-03-31 Verax Corporation Weighted microsponge for immobilizing bioactive material
US5153132A (en) 1988-06-30 1992-10-06 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Three-dimensional co-culture process
US5300285A (en) 1992-10-13 1994-04-05 Dow Corning Corporation Permanent waving with silicones
US5320796A (en) 1992-04-30 1994-06-14 Dow Corning Toray Silicone Co., Ltd. Method for the preparation of powder mixtures
US5358935A (en) 1992-11-19 1994-10-25 Robert Allen Smith Nonantigenic keratinous protein material
US5512474A (en) 1992-05-29 1996-04-30 Bsi Corporation Cell culture support containing a cell adhesion factor and a positively-charged molecule
US5636643A (en) 1991-11-14 1997-06-10 Wake Forest University Wound treatment employing reduced pressure
US5645081A (en) 1991-11-14 1997-07-08 Wake Forest University Method of treating tissue damage and apparatus for same
US5651966A (en) 1992-05-29 1997-07-29 The University Of North Carolina At Chapel Hill Pharmaceutically acceptable fixed-dried human blood platelets
US5651960A (en) 1995-09-22 1997-07-29 Helene Curtis, Inc. Method and composition for removing semi-permanent color from human hair
US5679819A (en) 1995-04-04 1997-10-21 Croda International Plc Cystine-silicone copolymers and their use for treating keratin substrates
US5707972A (en) 1993-08-25 1998-01-13 Shimizu Chemical Corporation Hydrophilic polysaccharide-based pharmaceutical perparation for external use
US5763583A (en) 1993-05-24 1998-06-09 Kao Corporation Process for producing solubilized protein
US5852024A (en) 1997-02-11 1998-12-22 Hadasit Treatment and prevention of adhesions
US5883078A (en) 1995-06-12 1999-03-16 Immuno Aktiengesellschaft Hemostyptic and tissue adhesive
WO1999026595A1 (fr) 1997-11-26 1999-06-03 Keraplast Technologies, Ltd. Hydrogel a base de keratine destine a des applications biomedicales et son procede de fabrication
WO1999026570A1 (fr) 1997-11-26 1999-06-03 Keraplast Technologies, Ltd. Technique de reticulation de film, de feuilles et de materiau en vrac a base de keratine
US5948432A (en) 1997-11-26 1999-09-07 Keraplast Technologies Ltd. Keratin-based sheet material for biomedical applications and method of production
WO1999051175A1 (fr) 1998-04-08 1999-10-14 Keraplast Technologies Ltd. Matiere proteique keratinique a effet cicatrisant et son procede de fabrication
US5972335A (en) 1994-03-29 1999-10-26 The Victoria University Of Manchester Wound healing
WO2000076437A1 (fr) 1999-06-11 2000-12-21 Keraplast Technologies, Ltd. Peptide de keratine soluble
WO2001019283A2 (fr) 1999-09-13 2001-03-22 Keraplast Technologies Ltd. Prothese implantable ou expansible dans les tissus
WO2001019305A1 (fr) 1999-09-13 2001-03-22 Keraplast Technologies Ltd. Keratine absorbant l'eau et gel fabrique avec de la keratine
US6251379B1 (en) 1999-02-26 2001-06-26 Shiseido Co., Ltd. Hair cosmetic composition
US6268454B1 (en) 1999-10-06 2001-07-31 Pacific Corporation Amino acid silicon polymer, method for preparing the same, cosmetic particles surface-treated with the same, and cosmetic composition containing the particles
US6270793B1 (en) 1999-09-13 2001-08-07 Keraplast Technologies, Ltd. Absorbent keratin wound dressing
US6274155B1 (en) 1999-09-13 2001-08-14 Keraplast Technologies, Ltd. Nonwoven sheet and film containing water absorbent keratin
WO2001064033A2 (fr) 2000-03-01 2001-09-07 Keraplast Technologies, Ltd. Forme hydratable de keratine utilisee dans l'amendement des sols
US20010021389A1 (en) 1997-04-01 2001-09-13 Cap Biotechnology, Inc. Calcium phosphate microcarriers and microsphers
WO2002045508A1 (fr) 2000-12-08 2002-06-13 Abe Widra Utilisation de l'alpha-keratose en tant que substitut du plasma sanguin
US6461628B1 (en) 1999-09-13 2002-10-08 Keraplast Technologies, Ltd. Non-woven keratin cell scaffold
US20020192196A1 (en) 1998-07-13 2002-12-19 Allen-Hoffmann B. Lynn Method and composition for skin grafts
WO2003011894A1 (fr) 2001-07-17 2003-02-13 Keratec Limited Elaboration de derives de keratine solubles
US20030049266A1 (en) 2000-12-27 2003-03-13 Fearon Karen L. Immunomodulatory polynucleotides and methods of using the same
US20030109587A1 (en) 2000-05-22 2003-06-12 Yuichi Mori Gelling composition
WO2003064449A2 (fr) 2002-01-28 2003-08-07 Keraplast Technologies, Ltd. Peptides bioactifs de keratine
US6634945B2 (en) 2001-09-28 2003-10-21 Igt Gaming device having independent bonus reels
WO2003086491A2 (fr) 2002-04-10 2003-10-23 Keraplast Technologies, Ltd. Pansements pour anomalie tissulaire comprenant des reseaux proteiques
US20030204037A1 (en) 2002-04-10 2003-10-30 Van Dyke Mark E. Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks
WO2004011052A1 (fr) 2002-07-25 2004-02-05 Keraplast Technologies, Ltd. Revetement bioactif pour dispositifs medicaux comprenant de la keratine
US6696073B2 (en) 1999-02-23 2004-02-24 Osteotech, Inc. Shaped load-bearing osteoimplant and methods of making same
US20040062793A1 (en) 2002-07-05 2004-04-01 Dyke Mark Van Tissue defect dressings comprising proteinaceous networks
US20040078090A1 (en) 2002-10-18 2004-04-22 Francois Binette Biocompatible scaffolds with tissue fragments
US20040120910A1 (en) 2002-04-10 2004-06-24 Dyke Mark Van Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks
US6783546B2 (en) 1999-09-13 2004-08-31 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
US6808927B2 (en) 2001-04-04 2004-10-26 American Diagnostica, Inc. Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (TAFI) and methods of use thereof
US6825323B2 (en) 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US6833488B2 (en) 2001-03-30 2004-12-21 Exotech Bio Solution Ltd. Biocompatible, biodegradable, water-absorbent material and methods for its preparation
US20040267362A1 (en) 2003-06-30 2004-12-30 Julia Hwang Scaffold for connective tissue repair
US6858383B2 (en) 2000-12-22 2005-02-22 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US6869445B1 (en) 2000-05-04 2005-03-22 Phillips Plastics Corp. Packable ceramic beads for bone repair
US20050084542A1 (en) 2003-04-11 2005-04-21 Rosenberg Aron D. Osteoinductive bone material
US20060051732A1 (en) 2004-08-17 2006-03-09 Van Dyke Mark E Ambient stored blood plasma expanders
US20060140889A1 (en) * 2002-12-10 2006-06-29 L-Mabs B.V. Affinity proteins for controlled application of cosmetic substances
WO2007050387A2 (fr) 2005-10-21 2007-05-03 Wake Forest University Health Sciences Compositions de bioceramique a la keratine
WO2007095151A2 (fr) 2006-02-10 2007-08-23 Wake Forest University Health Sciences Régénération nerveuse utilisant des bio-matériaux de kératine
WO2007098114A2 (fr) 2006-02-17 2007-08-30 Wake Forest University Health Sciences Compositions contenant des biomatériaux à base de kératine, destinées à induire la coagulation et la guérison
US20070208134A1 (en) 2005-10-03 2007-09-06 Hunter William L Anti-scarring drug combinations and use thereof
US20070207111A1 (en) * 2004-03-31 2007-09-06 Tokyo Univ Of Agriculture And Tech Tlo Co., Ltd. Process For Producing Solubilized Keratin
US20080003676A1 (en) 2006-06-26 2008-01-03 Millipore Corporation Growth of embryonic stem cells
US20080038327A1 (en) 2003-12-19 2008-02-14 Robert James Kelly Wound Care Products Containing Keratin
WO2008070091A1 (fr) 2006-12-06 2008-06-12 Keratec, Ltd. Matériaux de remplissage de vide osseux, et leurs procédés de fabrication
WO2008130607A2 (fr) 2007-04-17 2008-10-30 Wake Forest University Health Sciences Compositions de cicatrisation contenant des biomatériaux kératiniques
US20080274165A1 (en) 2006-02-17 2008-11-06 Wake Forest University Health Sciences Wound healing compositions containing keratin biomaterials
US20090017031A1 (en) 2003-02-21 2009-01-15 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
US20090047260A1 (en) 2007-08-17 2009-02-19 Wake Forest University Health Sciences Keratin biomaterials for cell culture and methods of use
US20090209738A1 (en) * 2004-10-21 2009-08-20 Robin William Cranston Method for separating keratinous proteins from materials
US20100197021A1 (en) 2007-08-17 2010-08-05 Van Dyke Mark E Keratin biomaterials for cell culture and methods of use
US7892572B2 (en) 2002-06-10 2011-02-22 Keraplast Technologies, Ltd. Orthopaedic materials derived from keratin
CN102120753A (zh) 2010-12-23 2011-07-13 暨南大学 一种改性角蛋白材料及其制备方法和应用
US20110217285A1 (en) 2010-03-08 2011-09-08 Van Dyke Mark E Keratin biomaterials for treatment of ischemia
US20110217356A1 (en) 2010-03-05 2011-09-08 Van Dyke Mark E Controlled delivery system
WO2012068376A2 (fr) 2010-11-17 2012-05-24 Wake Forest University Health Sciences Compositions kératiniques pour le traitement d'une déficience ou lésion osseuse
US20120219667A1 (en) 2009-07-02 2012-08-30 Keraplast Technologies, Ltd. Nutritional Supplement
US20120276188A1 (en) 2010-01-05 2012-11-01 Cell Constructs ,Inc. a corporation Biomaterials made from human hair
WO2013025940A1 (fr) 2011-08-17 2013-02-21 Keranetics Llc Angiogenèse induite par l'alpha-kératose
WO2013025928A2 (fr) 2011-08-17 2013-02-21 Keranetics Llc Procédés d'extraction de protéines de la kératine
WO2013025941A1 (fr) 2011-08-17 2013-02-21 Keranetics Llc Compositions gélifiantes à faible concentration en protéines
WO2016100476A1 (fr) 2014-12-16 2016-06-23 KeraNetics, LLC Charges dermiques comprenant des biomatériaux de kératine
US20160324750A1 (en) 2012-11-06 2016-11-10 Keranetics Llc White Keratin Compositions
US9827245B2 (en) 2013-03-15 2017-11-28 KeraNetics, LLC Keratin compositions comprising halofuginone

Patent Citations (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB351600A (en) 1930-04-04 1931-07-02 Ig Farbenindustrie Ag Improvements in the culture of micro-organisms intended for unhairing purposes
US2993794A (en) 1958-06-25 1961-07-25 Gen Foods Corp Process for preparing keratin protein
US3464825A (en) 1967-02-28 1969-09-02 Gen Mills Inc Keratin protein product and process of preparing same
US4570629A (en) 1982-03-17 1986-02-18 University Of Illinois Foundation Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same
US5100783A (en) 1985-05-10 1992-03-31 Verax Corporation Weighted microsponge for immobilizing bioactive material
US5006467A (en) 1987-07-03 1991-04-09 Mitsubishi Kasei Corporation Cell culture microcarriers
US5153132A (en) 1988-06-30 1992-10-06 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Three-dimensional co-culture process
US5047249A (en) 1988-07-22 1991-09-10 John Morris Co., Inc. Compositions and methods for treating skin conditions and promoting wound healing
US5636643A (en) 1991-11-14 1997-06-10 Wake Forest University Wound treatment employing reduced pressure
US5645081A (en) 1991-11-14 1997-07-08 Wake Forest University Method of treating tissue damage and apparatus for same
US5320796A (en) 1992-04-30 1994-06-14 Dow Corning Toray Silicone Co., Ltd. Method for the preparation of powder mixtures
US5512474A (en) 1992-05-29 1996-04-30 Bsi Corporation Cell culture support containing a cell adhesion factor and a positively-charged molecule
US5651966A (en) 1992-05-29 1997-07-29 The University Of North Carolina At Chapel Hill Pharmaceutically acceptable fixed-dried human blood platelets
US5902608A (en) 1992-05-29 1999-05-11 University Of North Carolina At Chapel Hill Surgical aids containing pharmaceutically acceptable fixed-dried human blood platelets
US5300285A (en) 1992-10-13 1994-04-05 Dow Corning Corporation Permanent waving with silicones
US5358935A (en) 1992-11-19 1994-10-25 Robert Allen Smith Nonantigenic keratinous protein material
US5763583A (en) 1993-05-24 1998-06-09 Kao Corporation Process for producing solubilized protein
US5707972A (en) 1993-08-25 1998-01-13 Shimizu Chemical Corporation Hydrophilic polysaccharide-based pharmaceutical perparation for external use
US5972335A (en) 1994-03-29 1999-10-26 The Victoria University Of Manchester Wound healing
US5679819A (en) 1995-04-04 1997-10-21 Croda International Plc Cystine-silicone copolymers and their use for treating keratin substrates
US5883078A (en) 1995-06-12 1999-03-16 Immuno Aktiengesellschaft Hemostyptic and tissue adhesive
US5651960A (en) 1995-09-22 1997-07-29 Helene Curtis, Inc. Method and composition for removing semi-permanent color from human hair
US5852024A (en) 1997-02-11 1998-12-22 Hadasit Treatment and prevention of adhesions
US20010021389A1 (en) 1997-04-01 2001-09-13 Cap Biotechnology, Inc. Calcium phosphate microcarriers and microsphers
US5932552A (en) 1997-11-26 1999-08-03 Keraplast Technologies Ltd. Keratin-based hydrogel for biomedical applications and method of production
US5948432A (en) 1997-11-26 1999-09-07 Keraplast Technologies Ltd. Keratin-based sheet material for biomedical applications and method of production
US6432435B1 (en) 1997-11-26 2002-08-13 Keraplast Technologies, Ltd. Keratin-based tissue engineering scaffold
WO1999026570A1 (fr) 1997-11-26 1999-06-03 Keraplast Technologies, Ltd. Technique de reticulation de film, de feuilles et de materiau en vrac a base de keratine
US6110487A (en) 1997-11-26 2000-08-29 Keraplast Technologies Ltd. Method of making porous keratin scaffolds and products of same
US6124265A (en) 1997-11-26 2000-09-26 Keraplast Technologies, Ltd. Method of making and cross-linking keratin-based films and sheets
US6159496A (en) 1997-11-26 2000-12-12 Keraplast Technologies, Ltd. Keratin-based hydrogel for biomedical applications and method of production
US6159495A (en) 1997-11-26 2000-12-12 Keraplast Technologies, Ltd. Porous and bulk keratin bio-polymers
US6379690B2 (en) 1997-11-26 2002-04-30 Keraplast Technologies, Ltd. Keratin-based hydrogel for biomedical applications and method of production
US6165496A (en) 1997-11-26 2000-12-26 Keraplast Technologies, Ltd. Keratin-based sheet material for biomedical applications and method of production
WO1999026595A1 (fr) 1997-11-26 1999-06-03 Keraplast Technologies, Ltd. Hydrogel a base de keratine destine a des applications biomedicales et son procede de fabrication
WO1999051175A1 (fr) 1998-04-08 1999-10-14 Keraplast Technologies Ltd. Matiere proteique keratinique a effet cicatrisant et son procede de fabrication
US6274163B1 (en) 1998-04-08 2001-08-14 Keraplast Technologies, Ltd. Keratinous protein material for wound healing applications and method
US20020192196A1 (en) 1998-07-13 2002-12-19 Allen-Hoffmann B. Lynn Method and composition for skin grafts
US6696073B2 (en) 1999-02-23 2004-02-24 Osteotech, Inc. Shaped load-bearing osteoimplant and methods of making same
US6251379B1 (en) 1999-02-26 2001-06-26 Shiseido Co., Ltd. Hair cosmetic composition
US6270791B1 (en) 1999-06-11 2001-08-07 Keraplast Technologies, Ltd. Soluble keratin peptide
WO2000076437A1 (fr) 1999-06-11 2000-12-21 Keraplast Technologies, Ltd. Peptide de keratine soluble
US20010047082A1 (en) 1999-06-11 2001-11-29 Van Dyke Mark E. Soluble keratin peptide
WO2001019305A1 (fr) 1999-09-13 2001-03-22 Keraplast Technologies Ltd. Keratine absorbant l'eau et gel fabrique avec de la keratine
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US20050169963A1 (en) 1999-09-13 2005-08-04 Southwest Ressearch Institute Implantable prosthetic or tissue expanding device
US6371984B1 (en) 1999-09-13 2002-04-16 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
US6274155B1 (en) 1999-09-13 2001-08-14 Keraplast Technologies, Ltd. Nonwoven sheet and film containing water absorbent keratin
US6783546B2 (en) 1999-09-13 2004-08-31 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
US6270793B1 (en) 1999-09-13 2001-08-07 Keraplast Technologies, Ltd. Absorbent keratin wound dressing
US6461628B1 (en) 1999-09-13 2002-10-08 Keraplast Technologies, Ltd. Non-woven keratin cell scaffold
US6316598B1 (en) 1999-09-13 2001-11-13 Keraplast Technologies, Ltd. Water absorbent keratin and gel formed therefrom
US20040076599A1 (en) 1999-09-13 2004-04-22 Southwest Research Institute Keratin-based powders and hydrogel for pharmaceutical applications
WO2001019283A2 (fr) 1999-09-13 2001-03-22 Keraplast Technologies Ltd. Prothese implantable ou expansible dans les tissus
US6268454B1 (en) 1999-10-06 2001-07-31 Pacific Corporation Amino acid silicon polymer, method for preparing the same, cosmetic particles surface-treated with the same, and cosmetic composition containing the particles
WO2001064033A2 (fr) 2000-03-01 2001-09-07 Keraplast Technologies, Ltd. Forme hydratable de keratine utilisee dans l'amendement des sols
US6869445B1 (en) 2000-05-04 2005-03-22 Phillips Plastics Corp. Packable ceramic beads for bone repair
US20030109587A1 (en) 2000-05-22 2003-06-12 Yuichi Mori Gelling composition
WO2002045508A1 (fr) 2000-12-08 2002-06-13 Abe Widra Utilisation de l'alpha-keratose en tant que substitut du plasma sanguin
US6746836B1 (en) 2000-12-08 2004-06-08 Abe Widra Alpha-keratose as a blood plasma expander and use thereof
US6858383B2 (en) 2000-12-22 2005-02-22 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US20030049266A1 (en) 2000-12-27 2003-03-13 Fearon Karen L. Immunomodulatory polynucleotides and methods of using the same
US6825323B2 (en) 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US6833488B2 (en) 2001-03-30 2004-12-21 Exotech Bio Solution Ltd. Biocompatible, biodegradable, water-absorbent material and methods for its preparation
US6808927B2 (en) 2001-04-04 2004-10-26 American Diagnostica, Inc. Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (TAFI) and methods of use thereof
US7148327B2 (en) 2001-07-17 2006-12-12 Keratec Limited Production of soluble keratin derivaties
WO2003011894A1 (fr) 2001-07-17 2003-02-13 Keratec Limited Elaboration de derives de keratine solubles
US6634945B2 (en) 2001-09-28 2003-10-21 Igt Gaming device having independent bonus reels
US20030228353A1 (en) 2002-01-28 2003-12-11 Keraplast Technologies, Ltd. Bioactive keratin peptides
WO2003064449A2 (fr) 2002-01-28 2003-08-07 Keraplast Technologies, Ltd. Peptides bioactifs de keratine
US20030204037A1 (en) 2002-04-10 2003-10-30 Van Dyke Mark E. Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks
US20040120910A1 (en) 2002-04-10 2004-06-24 Dyke Mark Van Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks
WO2003086491A2 (fr) 2002-04-10 2003-10-23 Keraplast Technologies, Ltd. Pansements pour anomalie tissulaire comprenant des reseaux proteiques
US7892572B2 (en) 2002-06-10 2011-02-22 Keraplast Technologies, Ltd. Orthopaedic materials derived from keratin
US20040062793A1 (en) 2002-07-05 2004-04-01 Dyke Mark Van Tissue defect dressings comprising proteinaceous networks
WO2004011052A1 (fr) 2002-07-25 2004-02-05 Keraplast Technologies, Ltd. Revetement bioactif pour dispositifs medicaux comprenant de la keratine
US20050058686A1 (en) 2002-07-25 2005-03-17 Mark Van Dyke Bioactive coating for medical devices
US20040078090A1 (en) 2002-10-18 2004-04-22 Francois Binette Biocompatible scaffolds with tissue fragments
US20060140889A1 (en) * 2002-12-10 2006-06-29 L-Mabs B.V. Affinity proteins for controlled application of cosmetic substances
US20090017031A1 (en) 2003-02-21 2009-01-15 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
US20050084542A1 (en) 2003-04-11 2005-04-21 Rosenberg Aron D. Osteoinductive bone material
US20040267362A1 (en) 2003-06-30 2004-12-30 Julia Hwang Scaffold for connective tissue repair
US20080038327A1 (en) 2003-12-19 2008-02-14 Robert James Kelly Wound Care Products Containing Keratin
US20070207111A1 (en) * 2004-03-31 2007-09-06 Tokyo Univ Of Agriculture And Tech Tlo Co., Ltd. Process For Producing Solubilized Keratin
US8021830B2 (en) 2004-08-17 2011-09-20 Wake Forest University Health Sciences Method for increasing plasma volume by administering a plasma expander comprising basic alpha keratose
US7439012B2 (en) 2004-08-17 2008-10-21 Wake Forest University Health Sciences Ambient stored blood plasma expanders containing keratose
US20110300193A1 (en) 2004-08-17 2011-12-08 Van Dyke Mark E Ambient stored blood plasma expanders
US20090017001A1 (en) 2004-08-17 2009-01-15 Wake Forest University Health Sciences Ambient stored blood plasma expanders
WO2007001339A2 (fr) 2004-08-17 2007-01-04 Wake Forest University Health Sciences Succedanes du plasma sanguin stockes a temperature ambiante
US20060051732A1 (en) 2004-08-17 2006-03-09 Van Dyke Mark E Ambient stored blood plasma expanders
US20090209738A1 (en) * 2004-10-21 2009-08-20 Robin William Cranston Method for separating keratinous proteins from materials
US20070208134A1 (en) 2005-10-03 2007-09-06 Hunter William L Anti-scarring drug combinations and use thereof
US20070166348A1 (en) 2005-10-21 2007-07-19 Van Dyke Mark E Keratin bioceramic compositions
WO2007050387A2 (fr) 2005-10-21 2007-05-03 Wake Forest University Health Sciences Compositions de bioceramique a la keratine
US20070298070A1 (en) 2006-02-10 2007-12-27 Van Dyke Mark E Nerve regeneration employing keratin biomaterials
US20110137329A1 (en) 2006-02-10 2011-06-09 Dyke Mark E Van Nerve regeneration employing keratin biomaterials
US7892573B2 (en) 2006-02-10 2011-02-22 Wake Forest University Health Sciences Nerve regeneration employing keratin biomaterials
WO2007095151A2 (fr) 2006-02-10 2007-08-23 Wake Forest University Health Sciences Régénération nerveuse utilisant des bio-matériaux de kératine
WO2007098114A2 (fr) 2006-02-17 2007-08-30 Wake Forest University Health Sciences Compositions contenant des biomatériaux à base de kératine, destinées à induire la coagulation et la guérison
US8299013B2 (en) 2006-02-17 2012-10-30 Wake Forest University Health Sciences Clotting and healing compositions containing keratin biomaterials
WO2007098053A2 (fr) 2006-02-17 2007-08-30 Wake Forest University Health Sciences Revêtements et implants biomédicaux constitués de biomatériaux de kératine
US8273702B2 (en) 2006-02-17 2012-09-25 Wake Forest University Health Sciences Wound healing compositions containing keratin biomaterials
US20090004242A1 (en) 2006-02-17 2009-01-01 Van Dyke Mark E Coatings and Biomedical Implants Formed From Keratin Biomaterials
US20080274165A1 (en) 2006-02-17 2008-11-06 Wake Forest University Health Sciences Wound healing compositions containing keratin biomaterials
US20110142910A1 (en) 2006-02-17 2011-06-16 Van Dyke Mark E Clotting and Healing Compositions Containing Keratin Biomaterials
US8258093B2 (en) 2006-02-17 2012-09-04 Wake Forest University Health Sciences Wound healing compositions containing keratin biomaterials
US20080003676A1 (en) 2006-06-26 2008-01-03 Millipore Corporation Growth of embryonic stem cells
WO2008070091A1 (fr) 2006-12-06 2008-06-12 Keratec, Ltd. Matériaux de remplissage de vide osseux, et leurs procédés de fabrication
WO2008130607A2 (fr) 2007-04-17 2008-10-30 Wake Forest University Health Sciences Compositions de cicatrisation contenant des biomatériaux kératiniques
US20100197021A1 (en) 2007-08-17 2010-08-05 Van Dyke Mark E Keratin biomaterials for cell culture and methods of use
US20090047260A1 (en) 2007-08-17 2009-02-19 Wake Forest University Health Sciences Keratin biomaterials for cell culture and methods of use
WO2010093882A1 (fr) 2009-02-13 2010-08-19 Wake Forest University Health Sciences Biomatériaux de kératine pour culture de cellules et procédés d'utilisation
US20120219667A1 (en) 2009-07-02 2012-08-30 Keraplast Technologies, Ltd. Nutritional Supplement
US20120276188A1 (en) 2010-01-05 2012-11-01 Cell Constructs ,Inc. a corporation Biomaterials made from human hair
US20110217356A1 (en) 2010-03-05 2011-09-08 Van Dyke Mark E Controlled delivery system
WO2011109808A1 (fr) 2010-03-05 2011-09-09 Wake Forest University Health Sciences Système d'administration contrôlée
WO2011112575A1 (fr) 2010-03-08 2011-09-15 Wake Forest University Health Sciences Biomatériaux à base de kératine destinés à traiter l'ischémie
US20110217285A1 (en) 2010-03-08 2011-09-08 Van Dyke Mark E Keratin biomaterials for treatment of ischemia
WO2012068376A2 (fr) 2010-11-17 2012-05-24 Wake Forest University Health Sciences Compositions kératiniques pour le traitement d'une déficience ou lésion osseuse
CN102120753A (zh) 2010-12-23 2011-07-13 暨南大学 一种改性角蛋白材料及其制备方法和应用
WO2013025940A1 (fr) 2011-08-17 2013-02-21 Keranetics Llc Angiogenèse induite par l'alpha-kératose
WO2013025928A2 (fr) 2011-08-17 2013-02-21 Keranetics Llc Procédés d'extraction de protéines de la kératine
WO2013025941A1 (fr) 2011-08-17 2013-02-21 Keranetics Llc Compositions gélifiantes à faible concentration en protéines
US9700631B2 (en) 2011-08-17 2017-07-11 KeraNetics, LLC Low protein percentage gelling compositions
US20170281783A1 (en) 2011-08-17 2017-10-05 KeraNetics, LLC Low protein percentage gelling compositions
US20160324750A1 (en) 2012-11-06 2016-11-10 Keranetics Llc White Keratin Compositions
US9827245B2 (en) 2013-03-15 2017-11-28 KeraNetics, LLC Keratin compositions comprising halofuginone
WO2016100476A1 (fr) 2014-12-16 2016-06-23 KeraNetics, LLC Charges dermiques comprenant des biomatériaux de kératine

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
"Dialysis Methods for Protein Research", ThermoFisher Scientific, Retrieved from < https://www.thermofisher.com/us/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-protein-methods/dialysis-methods-protein-research.html > on Sep. 7, 2017. *
"Tangential Flow Filtration", PALL Laboratory, Retrieved from < https://laboratory.pall.com/en/tangential-flow-filtration.html > on Sep. 7, 2017. *
Barnstead/Lab-Line MAx Q 4000 Shaker Manual; Retrieved from < https://www.artisantg.com/info/ATGpajiz.pdf > on Sep. 6, 2017. *
De Guzman et al., Mechanical and biological properties of keratose biomaterials. Biomaterials. Nov. 2011;32 (32):8205-17.
Hill et al., Some properties of keratin biomaterials: kerateines. Biomaterials. Feb. 2010;31(4):585-93.
Mechanical Mixing-Retrieved from San Diego Miramar Collage ChemPages Laboratory Resources < http://faculty.sdmiramar.edu/fgarces/labmatters/chemtech/modules/mixing/mixmech.htm > on Mar. 6, 2018. *
Mechanical Mixing—Retrieved from San Diego Miramar Collage ChemPages Laboratory Resources < http://faculty.sdmiramar.edu/fgarces/labmatters/chemtech/modules/mixing/mixmech.htm > on Mar. 6, 2018. *
Millipore Tangential Flow Filtration from 2003 < http://wolfson.huji.ac.il/purification/PDF/dialysis/MILLIPORE_TFF.pdf > downloaded Mar. 16, 2018. *
Nakamura et al., "A Rapid Extraction Procedure of Human Hair Proteins and Identification of Phosphorylated Species", Biol. Pharm. Bull. 25(5) 569-572 (2002). *
Peters et al., Observations upon a compound of mustard gas and kerateine. Biochem J. 1947;41(4):550-5.
Peyton et al., Halofuginone infused keratin hydrogel attenuates adhesions in a rodent cecal abrasion model. J Surg Res. Dec. 2012;178(2):545-52.
Saul et al., Keratin hydrogels support the sustained release of bioactive ciprofloxacin. J Biomed Mater Res A. Sep. 15, 2011;98(4):544-53.
Science gateway Centrifuge Rotor Speed Calculator Tool-Retrieved from < http://www.sciencegateway.org/tools/rotor.htm > on Aug. 23, 2016. *
Science gateway Centrifuge Rotor Speed Calculator Tool—Retrieved from < http://www.sciencegateway.org/tools/rotor.htm > on Aug. 23, 2016. *
Sierpinski et al., "The use of keratin biomaterials derived from human hair for the promotion of rapid regeneration of peripheral nerves", Biomaterials 29 (2008) 118-128. *
Sorvall Evolution RC product information sheet (Thermo Scientific). Retreived from < https://www.thermofisher.com/content/dam/tfs/LPG/LED/LED%20Documents/Product%20Manuals%20&%20Specifications/Centrifuges/Benchtop%20Centrifuges/General%20Purpose%20Centirfuges/D17331˜.pdf> on Aug. 23, 2016. *
ThermoFisher Scientific Press Release, May 8, 2006-Merger of Thermo Electron and Fisher Scientific. Retrieved from < http://ir.thermofisher.com/investors/news-and-events/news-releases/news-release-details/2006/Thermo-Electron-and-Fisher-Scientific-to-Combine-in-Industry-Transforming-Transaction/default.aspx? > on Aug. 24, 2016. *
ThermoFisher Scientific Press Release, May 8, 2006—Merger of Thermo Electron and Fisher Scientific. Retrieved from < http://ir.thermofisher.com/investors/news-and-events/news-releases/news-release-details/2006/Thermo-Electron-and-Fisher-Scientific-to-Combine-in-Industry-Transforming-Transaction/default.aspx? > on Aug. 24, 2016. *
U.S. Appl. No. 14/215,601 filed Mar. 17, 2014 issued U.S. Pat. No. 9,827,245.
U.S. Appl. No. 14/238,672 filed Sep. 12, 2014 issued U.S. Pat. No. 9,700,631.
U.S. Appl. No. 14/704,211 filed May 5, 2015 published U.S. Pat. No. 2016-0324750.
U.S. Appl. No. 14/704,211, filed May 5, 2015.
U.S. Appl. No. 15/619,615 filed Jun. 12, 2017 published U.S. Pat. No. 2017-0281783.
U.S. Appl. No. 15/619,615, filed Jun. 12, 2017.

Also Published As

Publication number Publication date
CA2845266A1 (fr) 2013-02-21
US20190359650A1 (en) 2019-11-28
US11034722B2 (en) 2021-06-15
WO2013025928A2 (fr) 2013-02-21
WO2013025928A3 (fr) 2013-04-11
CA2845266C (fr) 2020-07-21
AU2012296477B2 (en) 2017-04-27
EP3412683A1 (fr) 2018-12-12
EP2744820B1 (fr) 2018-07-25
AU2012296477A1 (en) 2014-03-20
EP2744820A4 (fr) 2015-01-14
EP2744820A2 (fr) 2014-06-25
EP3412683B1 (fr) 2022-02-09
US20150080552A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
US11034722B2 (en) Methods for extracting keratin proteins
US10709789B2 (en) Low protein percentage gelling compositions
EP2674036B1 (fr) Production de protéine de colza
US8197852B2 (en) Process for solubilizing protein from a proteinaceous material and compositions thereof
US10400019B2 (en) Keratin nanomaterials and methods of production
JP4863433B2 (ja) 魚鱗由来コラーゲンの取得方法
US10792239B2 (en) White keratin compositions
WO2009119596A1 (fr) Procédé de classification de protéines, procédé de dissolution de protéines, procédé de fractionnement et de collecte de fibres non animales et de protéines provenant d&#39;une fibre animale
JP4351461B2 (ja) コラーゲンタンパク質からのエンドトキシン除去方法
KR102502522B1 (ko) 지방조직에서 세포외기질 및 콜라겐을 추출하는 방법
JP2009173678A (ja) コラーゲンタンパク質からのエンドトキシン除去方法
CN116554304A (zh) 一种胶原蛋白及其纯化方法、提取方法和应用
WO2014074591A1 (fr) Compositions de kératine blanche
CN117946250A (zh) 一种红鳍东方鲀鱼皮抗酪氨酸酶活性肽的制备方法
HU214641B (hu) Eljárás pörk és elhalt szövetek eltávolítására használható, eszkaráztartalmú proteolitikus keverék előállítására

Legal Events

Date Code Title Description
AS Assignment

Owner name: KERANETICS, LLC, NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOYD, SARAH ANN;REEL/FRAME:043097/0293

Effective date: 20170707

Owner name: KERANETICS, LLC, NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BURNETT, LUKE;REEL/FRAME:043097/0204

Effective date: 20170720

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

AS Assignment

Owner name: KERATIN BIOSCIENCES, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KERANETICS LLC;REEL/FRAME:048845/0027

Effective date: 20190403

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: KERANETICS, INC, NORTH CAROLINA

Free format text: CHANGE OF NAME;ASSIGNOR:KERATIN BIOSCIENCES INC.;REEL/FRAME:050383/0577

Effective date: 20190830

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4